Sahm Adrangi, The Gifted Financial Advisor at Kerrisdale Capital Management LLC

Mr. Sahm Adrangi has earned himself a place in the investment and financial industry for his remarkable contribution. In 2009, he founded Kerrisdale Capital Management LLC, a company that centers on unique event-driven situations and long-standing value investments. Since its foundation, Mr. Adrangi has served the company as the Founder and Chief Investment Officer (CIO). Based on his role in the company, he has been active in all aspects of its management and development over the years.

Mr. Adrangi is not a novice in financial management. He has a precious and valuable experience stemming from his previous positions in the investment and financial industry. He has served as the investment analyst at Investment Analyst at Longacre Fund Management, LLC. He has also worked at Chanin Capital Partners in the Bankruptcy Restructuring group. At Chanin Capital, he advised creditors in and out of court alongside Chapter 11 bankruptcy rearrangements. Deutsche Bank, he helped reorganize the bank debt and high yield bonds, buyout and exit financing and debt refinancing. Sahm Adrangi is a holder of a Bachelor of Arts in Economics from Yale University.

Sahm Adrangi is a transformational leader. He has developed Kerrisdale Capital into a reputable research-oriented company that manages over $300 million. The firm is a leading proponent of soft activism investing approach. It focuses on creating investment impetus by sharing informed investment insights with the broader investment community. Kerrisdale Capital Management shares information through its website and other third-party websites.

In a recent research-based article, Sahm Adrangi advised that St. Joe’s Land Holdings are over-hyped and not worth the stated valuation. He further disclosed that its largest shareholder, Fairholme Fund was subject to SEC liquidity rules that will oblige it to reduce its stake, effectively increasing the risk of selling an overestimated optimism. The Bay-Walton Sector Plan remained stalled, and the recurrent revenue from commercial development proved immaterial.

Kerrisdale capital also conducted an objective analysis of suspicious traffic to QuinStreet’s network of proprietary and affiliated websites. Sahm Adrangi disclosed that QuinStreet is a low-quality firm with a misinformed business model. Its growth came from a single client, which was a fact that the market had overlooked.

https://www.businessinsider.com/meet-hedge-funder-sahm-adrangi-2013-10

October 3, 2018

Posted In: Business, Businessman, CEO, Entrepreneur, Market Leader

Tags: , , , , , , , , , , , , , ,

Sahm Adrangi Is Taking The Short Side With Proteostasis With Latest Negative Report From Kerrisdale

Sahm Adrangi is a well-known man in the investing world thanks to his many accomplishments as an investor and his success at Kerrisdale Capital. This private investment firm invests in various companies around the world. Today, being able to identify quality companies in the stock market is a challenge, and Sahm Adrangi is standing out where not many can. Kerrisdale has managed to excel and come out on top of the S&P 500 for several successive quarters.

On a normal basis, Kerrisdale Capital puts out reports on various companies in the market, and their latest was quite the negative report against biotech firm Proteostasis. This biotech company is home to Cambridge and has recently been making claims of a new breakthrough in terms of cystic fibrosis. Their new drug in development, PTI-428, is aimed at helping increasing lung performance in patients.

Unfortunately for Proteostasis, Kerrisdale was not impressed with their figures and the data they released, so Sahm Adrangi decided to do a little more digging into the company. Upon even closer examination of the results of the company, their actual test sample was extremely small. So small in fact, PTI-428 was only tested on four patients. This is not nearly enough to make such claims the company has been making, causing their company stock value to go up.

Kerrisdale took quickly to their report to get it out as soon as possible to inform the public and many investors out there of what is really behind this biotech company, Proteostasis. According to Sahm Adrangi, their drug cocktail is most likely an ineffective drug that works better as a placebo. Unfortunately for Proteostasis, the majority of their company value is invested in their product, which means they will lose more than 70% of their company share value when it comes out that PTI-428 is not effective.

As more companies and investors are becoming aware of the nature of this biotech company, their share values continue to drop and will likely push the company off the map in the near future.

http://www.imdb.com/name/nm1444924/

April 19, 2018

Posted In: Business, Business success, Businessman, CEO, Entrepreneur, Investor

Tags: , , , , , , , , ,